Four Governance Requirements for AI-Assisted Medical Content Review

An AI review system is not trustworthy because it can produce an answer. It is trustworthy when its role, evidence, changes, and human decision points are controlled.

The first question many teams ask about AI-assisted medical content review is whether the model can find a risk.

That is necessary, but it is not enough.

An enterprise review system also needs to answer a harder set of questions: What is the system allowed to do? Which evidence supports each flag? What happens when a model or rule changes? Who remains accountable for the final decision?

An AI review system is not trustworthy because it can produce an answer. It is trustworthy when its role, evidence, changes, and decision boundaries are controlled.

This is especially important before formal MLR approval, where AI output may influence how Medical, Legal, Regulatory, and Compliance teams allocate attention—even when the AI does not make the final decision.

Regulatory direction: governance should follow the context of use

Regulators are developing AI principles across the medicinal-product lifecycle, but the practical direction is already clear: oversight should be proportionate to how an AI system is used and how much its output can affect a regulated decision.

The FDA's 2025 draft framework for AI used to support drug and biological-product regulatory decisions applies a risk-based credibility approach anchored in the model's context of use. Joint FDA and EMA principles for good AI practice also emphasize human-centric design, clear context of use, data governance, risk-based performance assessment, and lifecycle management. The EMA's reflection paper similarly frames AI governance across development, authorization, and post-authorization settings.

These documents do not create one universal validation checklist for every MLR pre-review tool. Medical content review has its own workflow, data, and decision boundaries. But they offer a useful design principle:

Start with the decision the AI supports—not with the model the vendor wants to deploy.

For medical content review, that principle can be translated into four governance requirements.

Requirement 1: Define the context of use and decision rights

"AI-assisted review" is too broad to govern.

A system that highlights a potentially missing reference has a different risk profile from one that automatically blocks distribution. A system that compares a draft against an approved claim library has a different role from one that interprets whether a scientific statement is acceptable in a specific market.

A usable context-of-use definition should state:

• which material types are in scope;
• which review points the system can assess;
• which source libraries, SOPs, and market rules it may use;
• what output it produces: candidate, warning, recommendation, or workflow route;
• who reviews that output;
• what downstream action the output can trigger;
• which decisions remain outside the system's authority.

For example:

The system flags possible claim-reference mismatches in HCP-facing slide decks before formal MLR approval. It shows the claim, source candidate, page location, and comparison rationale. A qualified reviewer decides whether the claim is adequately supported.

That definition is more governable than "the AI reviews claims." It gives product, compliance, IT, and validation teams the same operating boundary.

Clear decision rights prevent decision support from quietly turning into decision automation.

Requirement 2: Preserve evidence lineage and review traceability

A model answer without evidence is difficult to review and difficult to defend.

Every material flag should connect to an inspectable evidence chain:

• the page and object where the issue appears;
• the relevant text, image, chart, footnote, or reference;
• the SOP rule or approved source used for comparison;
• the version and effective date of that rule or source;
• the reason the system produced the flag;
• the human action that followed.

For example, "Reference mismatch detected" is not enough. A useful result shows the claim on slide 12, the cited publication, the approved wording or source passage, and the exact difference that needs review.

Traceability also applies to the review record. If a user overrides a recommendation, changes a risk category, or resolves an issue, the workflow should preserve who acted, when the action occurred, and why.

FDA data-integrity guidance describes an audit trail as a secure, time-stamped record that enables reconstruction of the creation, modification, or deletion of an electronic record. Not every pre-review workflow is a CGMP record, and the applicable requirements depend on the deployment context. The design lesson remains valuable: a review result should remain understandable after the moment it was generated.

Requirement 3: Manage rules and models through the full lifecycle

AI systems are not static.

Models change. Prompts change. OCR engines change. Approved claims are revised. SOPs gain exceptions. Market rules are updated. A workflow that performs well today can behave differently after any of these changes.

Lifecycle governance should therefore cover more than the foundation model. Teams should version and control:

• model and model-provider versions;
• prompts, system instructions, and tool configurations;
• review-point rules and thresholds;
• source libraries and approved-content repositories;
• material parsers, OCR, and image-processing components;
• routing logic and severity mappings;
• evaluation datasets and reviewer ground truth.

Every material change should trigger a proportionate assessment. That may include regression testing, focused review-point testing, comparison against a locked benchmark, or review of high-risk edge cases.

Useful evaluation should be segmented by the actual task:

• material type;
• review point;
• audience and market;
• text, image, chart, table, or QR-code object;
• false-positive and false-negative impact;
• frequency and reason for human overrides.

A single global accuracy score cannot show whether the system is reliable for a specific review decision.

Lifecycle management should also include a rollback path. If a rule update creates unexpected flags, the team needs to know which version was active, which materials were affected, and how to restore the previous behavior.

Requirement 4: Make human oversight operational

Human-in-the-loop should not be a disclaimer added at the bottom of a product page. It should be visible in the workflow.

Qualified reviewers need to be able to:

• inspect the evidence behind a flag;
• see uncertainty and conflicting signals;
• accept, reject, or modify the recommendation;
• document the reason for an override;
• escalate a case to the right Medical, Legal, Regulatory, or Compliance owner;
• distinguish routine issues from decisions requiring professional judgment.

The system should also define what happens when evidence is incomplete. "Unable to verify" is often a better result than a confident guess. A missing source, unreadable chart, unresolved product identity, or unavailable market rule should create an explicit review state.

The goal is not to keep a human click somewhere in the process. The goal is to give the human reviewer enough context and authority to make a meaningful decision.

AI should reduce the search burden while preserving human accountability.

A practical evaluation checklist

When evaluating an AI-assisted medical content review system, teams can ask:

1. Is the context of use defined for each review point?
2. Can each flag be traced to the page, object, source, and rule?
3. Are models, prompts, rules, and source libraries versioned?
4. Is performance evaluated by task and material type rather than one headline score?
5. Can reviewers override recommendations and record reasons?
6. Are unresolved or low-evidence cases routed explicitly?
7. Can the team reconstruct which system version reviewed a specific material?
8. Is there a tested change-control and rollback process?

These questions help separate a promising model demonstration from a review capability that can operate inside an enterprise workflow.

How ZENO fits into this model

ZENO is designed as an MLR pre-review layer, not an autonomous approval system.

It supports teams by identifying potential review risks, locating them in medical content materials, explaining the evidence and review logic involved, and routing issues for qualified human review before formal MLR approval.

The governance objective is straightforward: make the system's role explicit, make every important output reviewable, control changes over time, and keep accountable reviewers at the decision boundary.

That is how AI-assisted review becomes more than an isolated model call. It becomes a controlled part of the medical content workflow.